Literature DB >> 20609865

The complex clinical picture of side effects to anticoagulation.

Axel Trautmann1, Cornelia S Seitz.   

Abstract

Inflammatory plaques at injection sites are frequent side effects of heparin treatment and a clinical symptom of delayed-type hypersensitivity (DTH) to heparin. In most cases, changing the subcutaneous therapy from unfractionated to low-molecular-weight heparin or treatment with heparinoids does not provide improvement because of extensive cross-reactivity. Because of their completely different chemical structure, hirudins are a safe alternative for anticoagulation. Despite DTH to subcutaneously injected heparins, patients tolerate heparin intravenously. Therefore, in case of therapeutic necessity and DTH to heparins, the simple shift from subcutaneous to intravenous heparin administration is justified. Skin necrosis is a rare complication of anticoagulation. Heparin-induced skin necrosis is 1 of the symptoms of immune-mediated heparin-induced thrombocytopenia and should result in the immediate cessation of heparin therapy to prevent potentially fatal thrombotic events. This is in contrast to coumarin-induced skin necrosis, where therapy may be continued or restarted at a lower dose. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609865     DOI: 10.1016/j.mcna.2010.03.003

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

1.  Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.

Authors:  Andrew W Swartz; Jan Drappatz
Journal:  Oncologist       Date:  2021-02-09

2.  Recurrent intradialytic heparin induced anaphylaxis: workup and management.

Authors:  Amelia Santosa; Seng Hoe Tan; Yew Kuang Cheng
Journal:  Asia Pac Allergy       Date:  2013-10-31

3.  Allergic anaphylaxis due to subcutaneously injected heparin.

Authors:  Diana Anders; Axel Trautmann
Journal:  Allergy Asthma Clin Immunol       Date:  2013-01-10       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.